The long pentraxin 3 (PTX3): A novel prognostic inflammatory marker for mortality in acute chest pain

Thrombosis and Haemostasis

Volumn 102, Issue 3, 2009, Pages 555-563

  Brügger Andersen, Trygve ^a,b   Pönitz, Volker ^a,b   Kontny, Frederic ^c   Staines, Harry ^d   Grundt, Heidi ^a,b   Sagara, Mina ^e,f   Nilsen, W T ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c Volvat Medical Center   (Norway)

^d Sigma Statistical Services   (United Kingdom)

^e Perseus Proteomics   (Japan)

^f NOVARTIS PHARMA K K   (Japan)

Author keywords

Atherothrombosis; Chest pain; Clinical studies; Inflammation; Prognosis; PTX3

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTRAXIN 3; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; THORAX PAIN;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEST PAIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; SERUM AMYLOID P-COMPONENT; SIGNAL TRANSDUCTION; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449360718     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-02-0137     Document Type: Article

References (22)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366. (Pubitemid 40563173)
3. Alles VV, Bottazzi B, Peri G, et al. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994; 84: 3483-3493. (Pubitemid 24352913)
4. Klouche M, Peri G, Knabbe C, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004; 175: 221-228. (Pubitemid 38942901)
5. Rolph MS, Zimmer S, Bottazzi B, et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: e10-e14.
6. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-167. (Pubitemid 46360394)
7. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354. (Pubitemid 39407338)
8. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-641. (Pubitemid 30640663)
9. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-172.
10. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424. (Pubitemid 24247397)
11. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786-2792. (Pubitemid 36705987)
12. Kim H, Yang DH, Park Y, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J 2006; 70: 1379-1384. (Pubitemid 44672891)
13. Bogaty P, Boyer L, Simard S, et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 2008; 51: 2339-2346. (Pubitemid 351784544)
14. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007; 115: 962-971. (Pubitemid 46328289)
15. Brugger-Andersen T, Ponitz V, Staines H, et al. The prognostic utility of D-dimer and fibrin monomer at long-term follow-up after hospitalization with coronary chest pain. Blood Coagul Fibrinolysis 2008; 19: 701-707.
16. Muller-Bardorff M, Hallermayer K, Schroder A, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem 1997; 43: 458-466. (Pubitemid 27106481)
17. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993; 150: 1804-1812. (Pubitemid 23129656)
18. Lee GW, Goodman AR, Lee TH, et al. Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. J Immunol 1994; 153: 3700-3707.
19. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-1021. (Pubitemid 34940793)
20. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003; 41: 1264-1272.
21. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-2918. (Pubitemid 35424741)
22. Montalescot G, Dallongeville J, Van BE, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J 2007; 28: 1409-1417. (Pubitemid 47343817)